Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187696 | 0.98 | C3AR1 (0.45) | C3AR1GNPATNOD1SLC15A2FOLH1 | |
| SCHEMBL29476474 | 0.98 | C3AR1 (0.45) | C3AR1GNPATNOD1SLC15A2FOLH1 | |
| SCHEMBL2116832 | 0.98 | C3AR1 (0.45) | C3AR1GNPATNOD1SLC15A2FOLH1 | |
| SCHEMBL2815688 | 0.97 | C3AR1 (0.44) | C3AR1GNPATNOD1SLC15A2FOLH1 | |
| Benzene SCHEMBL6278673 | 0.95 | C3AR1 (0.49) | C3AR1GNPATNOD1SLC15A2FOLH1 | |
| SCHEMBL3952951 | 0.93 | SLC15A2 (0.44) | C3AR1GNPATNOD1SLC15A2NPY4R | |
| SCHEMBL29875780 | 0.93 | SLC15A2 (0.44) | C3AR1GNPATNOD1SLC15A2NPY4R | |
| SCHEMBL29875467 | 0.93 | SLC15A2 (0.44) | C3AR1GNPATNOD1SLC15A2NPY4R | |
| SCHEMBL3952924 | 0.93 | SLC15A2 (0.44) | C3AR1GNPATNOD1SLC15A2NPY4R | |
| SCHEMBL7764489 | 0.92 | C3AR1 (0.41) | C3AR1GNPATNOD1SLC15A2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | C3AR1 3287/4885GNPAT 4183/4885NOD1 3887/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | C3AR1 2632/4885GNPAT 4017/4885NOD1 3746/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | C3AR1 3287/4885GNPAT 4183/4885NOD1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.